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Objective: To assess a wide spectrum of biochemical markers (biomarkers) in a large cohort of individuals
with (very) early symptomatic knee and/or hip osteoarthritis (OA). Secondly, to investigate associations
between biomarkers and between biomarkers and demographics to demonstrate validity of the obtained
dataset and further investigate the involvement and/or role of these biomarkers in OA.
Design: Fourteen biomarkers (uCTX-II, uCTX-I, uNTX-I, sCOMP, sPIIANP, sCS846, sC1,2C, sOC, sPINP, sHA,
sPIIINP, pLeptin, pAdiponectin, pResistin) were assessed by ELISA or RIA in CHECK (Cohort Hip and Cohort
Knee), a 10-year prospective cohort of 1,002 individuals with early symptomatic knee and/or hip OA.
Results: Quality controls revealed that gathered data were technically reliable. The majority of biomarkers
showed relevant associations with demographic variables, which were expectedly different between
genders and/or menopausal status for some. Principal component analysis enabled identiﬁcation of ﬁve
clusters, consecutively designated as ‘bone-CTX-II’, ‘inﬂammation’, ‘synovium’, ‘C1,2C-adipokines’, and
‘cartilage synthesis’ cluster. Notably, uCTX-II clustered with biomarkers of bone metabolism, while
sCOMP clustered with biomarkers of synovial activity.
Conclusions: The identiﬁed clusters extended knowledge on individual biomarkers from mostly smaller
studies as did the observed associations between biomarker levels and demographics, from which
validity of our data was deduced. uCTX-II may not only reﬂect articular cartilage but also bone metabolism
and sCOMP may reﬂect synovial rather than cartilage metabolism. Major involvement of adipokines in
joint metabolism was not identiﬁed.
 2012 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) is a slowly-progressive, degenerative, low-
grade inﬂammatory joint disease that is commonly diagnosed in
a late stage when signiﬁcant joint damage has already occurred.
Tools for early-stage diagnosis may create an opportunity for
disease modifying treatment modalities. Development of such: W.E. van Spil, Department
ity Medical Center Utrecht,
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s Research Society International. Ptreatments is hampered by a poor understanding of OA patho-
genesis, the slowly-progressive character of OA, and insensitive
monitoring methods that necessitate long-term and large-scale
clinical trials1. Biochemical markers (biomarkers) could be valu-
able tools for early-stage OA diagnosis, follow-up of therapeutic
response, prediction of disease course, discrimination between OA
subtypes, and/or gaining further insight into OA pathogenesis. As
such, they might ultimately lead to improved diagnostic and ther-
apeutic modalities for OA.
Current knowledge of biomarkers is mainly based on data from
small cohorts and/or only one or a few simultaneously assessed
biomarkers2. Investigating small cohorts decreases statistical
power and increases the chance of coincidental ﬁndings, probably
partly explaining the inconsistent performance of biomarkers in
literature1,2. Moreover, assessing only one or a few biomarkers isublished by Elsevier Ltd. All rights reserved.
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Accordingly, the potential value of simultaneous assessment of
multiple biomarkers is increasingly recognized3.
Here we report on a large-scale assessment of 14 putative
biomarkers for OA in CHECK (Cohort Hip and Cohort Knee), a 10-
year prospective cohort of 1,002 participants with (very) early
symptomatic OA of knee and/or hip. Having a valid biomarker
dataset in addition to the many longitudinal radiographic and
clinical data that are available for all CHECK participants would
allow thorough investigation of cross-sectional and predictive
associations between biomarkers and OA parameters in (very)
early-stage knee and hip OA. In the current report, we discuss the
approach in this comprehensive biomarker assessment. We then
demonstrate its validity by investigating associations between
biomarkers and demographic variables and exploring mutual
associations between biomarkers. In addition, we extend hypoth-
eses on the biological backgrounds of some of the biomarkers.
Method
Cohort and sample collection
Biomarkers were assessed in baseline urine, serum, and plasma
samples of CHECK4. CHECK is a 10-year prospective cohort study of
1,002 individuals aged 45e65 years with pain and/or stiffness of
one and/or both knee(s) and/or hip(s). They had never or not longer
than 6 months ago consulted a physician for these symptoms.
Participants with any other pathological condition (e.g., other
rheumatic disease or joint trauma) that could explain the symp-
toms were excluded. All participants are broadly characterized
throughout follow-up: clinically through regular clinical examina-
tions and questionnaires, radiographically through knee and hip
radiographs at predeﬁned time points (at baseline and after 2, 5, 8,
and 10 years), and biochemically through collection of plasma,
serum, and urine samples at the time of radiography. Ultimately,
integration of all these aspects will aid to identiﬁcation of factors
that play a key role in the development and progression of OA.
CHECK is conducted according to the declaration of Helsinki (as
revised in 2000) and received approval from the ethics committee
of each of the involved medical centers. Written informed consent
was obtained from all participants before inclusion.
At baseline, participants (79.0% female) were aged 56  5 years
[mean  SD (standard deviation)] and had a BMI of 25.5 kg/m2
(median, 25e75% percentile 23.3e28.4). Women were designated
as postmenopausal when menstruation had stopped >12 months
before their baseline visit. When menopausal status could not beTable I
Simpliﬁed overview of the spectrum of biomarkers and adipokines that were assessed in
on a review article by Garnero et al.5. However, it should be emphasized that most biom
demonstrated for most of them. Reference numbers refer to references in the main text
Targeted OA process Biochemical marker
Cartilage degradation uCTX-II24,37e39
sCOMP31,46
Cartilage synthesis sPIIANP38,39
sCS84647
(Subchondral) bone degradation uCTX-I19,20,22,23,25
uNTX-I20,21
(Subchondral) bone synthesis sPINP19e21,25
sOC19,20,22,25,26
Synovial tissue synthesis sPIIINP41
Synovial tissue degradation and/or activity sHA42
Cartilage and (subchondral) bone degradation sC1,2C7
Adipokines pLeptin8
pAdiponectin7
pResistin9
* All ELISAs, except for UniQ PINP and PIIINP RIAs.deﬁned because of previous hysterectomy or bilateral ovariectomy,
oral anticonceptive use, or missing data, women aged >55 years
were designated as postmenopausal and menopausal status of
women aged 45e55 years was designated as undetermined.
Women using any sex hormonal therapy were also not included in
analyses including menopausal status. As such, 142 (17.9% of all
women) women were designated as premenopausal, 475 (60.0%)
postmenopausal, and 175 (22.1%) undetermined.
Of those participants with complete baseline radiographic data
for knees and hips (n ¼ 989), 24.6% showed only knee OA, 13.4%
showed only hip OA, 7.2% showed both knee and hip OA, while
54.8% showed OA of neither knee nor hip (OA deﬁned as K&L grade
1). Seventy-six percent of the participants with knee complaints
and 24% of the participants with hip complaints fulﬁlled the clinical
ACR criteria for the classiﬁcation of OA.
Sample tubes for plasma, serum, and urine were labeled with
participant identiﬁcation numbers at the time of collection. Non-
fasted serum, plasma, and second morning void urine samples
were collected between 8 and 12 a.m. and transportedwithin 4 h by
courier to the central laboratory (urine and plasma on ice, serum at
ambient temperature) where they were processed according to
protocols, regularly audited by a central coordinator. Gel serum
separation tubes were left at room temperature for at least 1 h to
allow clotting and centrifuged (15 min, 1,000e1,200 g). EDTA
plasma tubes were centrifuged (15 min, 2,000 g, 4C) and plasma
separated. Urine was collected in standard containers. All samples
were aliquoted and stored in cryotubes at 80C.Biomarkers
Eleven biomarkers of joint metabolism (Table I) were selected
on the basis of their performance as described in literature2 and so
that theywould represent complete joint metabolism, representing
anabolic as well as catabolic pathways in cartilage, (subchondral)
bone, and synovial tissue5 according to current understanding.
Since there is ambiguous data on the involvement of adipokines in
the pathogenesis of OA6e9, we additionally assessed three adipo-
kines (Table I).Assessment procedure
Biomarkers were assessed by commercially available ELISA or
RIA assays (Table I), according to manufacturer instructions. As
such, kits were not extensively (re)validated. To circumvent inter-
batch variability, all assay kits were purchased from singleCHECK. The targeted processes that are indicated per biomarker are primarily based
arkers cannot be considered joint speciﬁc and/or molecular validity is not deﬁnitely
Assay kit*
Urine Cartilaps EIA, Immunodiagnostic systems Ltd., Boldon, UK
Anamar Med AB, Göteborg, Sweden
Millipore Corp, Billerica, MA, US
IBEX, Montreal, Canada
Urine Crosslaps EIA, Immunodiagnostic systems Ltd., Boldon, UK
OSTEOMARK NTx Urine, Wampole Laboratories, Princeton, NJ, US
UniQ, Orion Diagnostica, Espoo, Finland
N-MID Osteocalcin ELISA, Immunodiagnostic systems Ltd., Boldon, UK
UniQ, Orion Diagnostica, Espoo, Finland
Corgenix Inc, Westminster, CO, US
IBEX, Montreal, Canada
BioVendor, Modrice, Czech Republic
BioVendor, Modrice, Czech Republic
BioVendor, Modrice, Czech Republic
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valued highly when purchasing the assay kits.
Triplicate assessment in a subset of at least 50 samples showed
adequate precision of singlicate as compared to triplicate assess-
ment (i.e., biomarker levels in the ﬁrst samples of triplets as
compared with mean biomarker levels in these triplets); intraclass
coefﬁcients10 were high (0.832) [Table SI]. Assessment was per-
formed in singlicate for all biomarkers in all samples.
Unexpectedly, the inﬂuence of multiple freezeethaw cycles and
storage time appeared to be not or only minimally investigated for
the selected biomarkers11e18. Therefore, it was decided that
biomarkers needed to be assessed on the day of thawing and that
samples needed to be thawed only once. This necessitated simul-
taneous assessment of multiple biomarkers per sample by several
technicians. Each technician worked on (a) speciﬁc biomarker(s) so
that each biomarker was assessed in all samples by the same
technician. Time plans were set up so that technicians were able to
perform several assay kits simultaneously. All technicians were
skilled in ELISA or RIA. One supervisor (NJ) coordinated logistics
and monitored continuity of procedures throughout the assess-
ment period. Each transition of samples or data took place
according to predeﬁned templates and was always checked by at
least two persons.
All samples were assessed within maximum 4 h after thawing.
Stability of the biomarkers during these 4 h was assumed on the
basis of manufacturer data and on the expected inherent stability of
(the epitopes of) matrix proteins. Prior to biomarker assessment,
samples were centrifuged (10 min, 2,000 g). All samples were
equally diluted for each biomarker. Of the approximately 14,000
assessments that were performed in total, a small minority showed
biomarker concentrations that were outside standard curves
(Table II). When these samples were re-assessed in the original as
well as adapted dilutions clear indications for unpredictable, non-
linear dilution effects were observed (data not shown). Therefore,
concentrations that were assessed in adapted dilution were
considered invalid. Thorough investigation of this issue (e.g., using
other than the supplied diluents) was not performed, because of
the very small number of samples concerned per biomarker. Since
omitting these samples from further analyses could introduce
a bias, samples that were too high or low were arbitrarily set on
120% of the maximum or 80% of the minimum biomarker level that
was assessed in participant samples, respectively. SensitivityTable II
Overview of numbers of successfully assessed samples, missing samples, and assessments
successfully assessed samples
N Missing Too low Too high Concentration (medi
uCTX-II 956 38 8 193 (132e281) ng/m
sCOMP 960 42 8.5 (7.2e9.9) U/l
sPIIANP 960 39 3 1,385 (1,087e1,771)
sCS846 963 39 70 (54e88) ng/ml
uCTX-I 954 38 10 152 (100e225) mg/m
uNTX-I 964 38 37 (28e51) nM BCE/
sPINP 962 39 1 42 (32e56) ng/ml
sOC 962 38 1 1 13 (10e17) ng/ml
sPIIINP 957 39 6 4.1 (3.5e4.9) ng/ml
sHA 952 38 12 27 (17e43) ng/ml
sC1,2C 958 40 4 0.17 (0.14e0.22) mg/
pLeptin 940 21 41 11.3 (6.2e19.4) ng/m
pAdiponectin 972 21 9 9.8 (7.3e14.0) mg/ml
pResistin 981 21 3.5 (3.0e4.3) ng/ml
Furthermore, intra-plate, inter-plate and between-day variability as calculated from rep
uCTX-II, uCTX-I, uNTX-I, sCOMP: three standard samples per plate, four plates per day, f
sPIIANP, sCS846, sC1,2C, sOC, sHA: three standard samples per plate, two plates per day
sPINP, sPIIINP: two standard samples per plate, two plates per day, eight days.
pAdiponectin, pLeptin, pResistin: three standard samples per plate, three plates per day
CV% (SD/mean * 100%).analyses without these arbitrarily set levels and with too high and
low levels set on 100% of maximum andminimumvalues were, and
will always be, performed.
Blank samples (assay buffer) that were incorporated at pre-
deﬁned positions in between samples were all at their predeﬁned
positions at the time of microplate reader assessment, indicating
that no major pipetting shifts had taken place. Internal control
samples as supplied by manufacturers (not available for sC1,2C and
sCS846) were incorporated in duplicate in each assay plate. Of
them, 87.1% fell within manufacturers’ ranges (data not shown).
Aberrant internal control samples were only minimally outside
reference ranges and in these cases the other control samples in
that plate were within the speciﬁed ranges. The higher internal
control samples of uNTX-I were consistently well below the
provided reference range. Although this possibly indicated an
aberrant course of the standard curve in the higher range, only
a minority of the participants’ samples showed uNTX-I concentra-
tions in this range and data were considered acceptable.
Urine, serum as well as plasma standard samples were self-
created by pooling samples from random OA outpatients and
frozen in aliquots. One standard sample aliquot was freshly thawed
on each assessment day and included in triplicate at predeﬁned
positions in all assay plates of that day. These standard sample data
were used to quantify precision of the assessments.
Urinary creatinine concentrations were assessed in an auto-
mated kinetic assay (UniCel DxC 800 Synchron Clinical System,
Beckman Coulter). hsCRP was assessed in all serum samples in an
automated nephelometric assay (BN II analyzer, Siemens).
For sC1,2C and sCS846 it was noticed that concentrations within
assay plates showed gradients from the ﬁrst to the last pipetted
sample (Spearman correlation analysis: rs between 0.516 and
0.263, P < 0.023 in eight of 14 plates). Despite thorough analyses
in consultancy with the involved manufacturer, no deﬁnite cause
for this phenomenon could be identiﬁed.
Statistics
Assessment precision was expressed as the coefﬁcient of vari-
ation (CV%, SD/mean value * 100%). Intra-plate CV%’s were calcu-
lated from the triplicate standard sample assessments that were
performed per assay plate and averaged for all plates. Inter-plate CV
%’s were calculated from the mean standard sample biomarkeroutside standard curves (too low and/or too high) as well as biomarker levels in the
an (25e75% perc)) Intra-plate CV% Inter-plate CV% Between-day CV%
mol 10.0 9.3 12.4
5.0 4.0 4.2
ng/ml 15.8 7.0 15.7
21.5 16.9 15.3
mol 9.7 6.1 2.7
mmol 14.9 6.6 10.7
4.4 4.5 6.2
3.4 4.1 4.3
5.4 3.2 7.2
15.1 13.0 17.3
ml 19.3 13.0 31.3
l 7.8 5.7 7.0
18.9 14.3 9.0
7.1 3.9 2.5
eated standard sample assessment in all assay plates are demonstrated.
our days.
, nine days.
, ﬁve days.
Table IIIA
Principal component analysis of biomarkers in all subjects, irrespective of radio-
graphic status (IIIA), and in subjects with radiographic OA only (IIIB). Structure
matrix showing factors with ‘eigenvalues’ >1 as obtained after Direct Oblimin
oblique rotation. Loading factors of biomarkers that were categorized per compo-
nent are depicted in bold, while other loading factors >0.300 in the component
concerned are depicted in italic. The communalities and scree plot are available in
the online supplementary data
1 2 3 4 5
uCTX-I 0.905 0.045 0.027 0.089 0.063
uNTX-I 0.861 0.102 0.004 0.103 0.113
sPINP 0.837 0.048 0.269 0.007 0.011
sOC 0.793 0.118 0.204 0.131 0.020
uCTX-II 0.547 0.342 0.355 0.116 0.213
ESR 0.059 0.744 0.054 0.159 0.020
pLeptin 0.043 0.725 0.105 0.138 0.107
hsCRP 0.192 0.722 0.041 0.377 0.123
sCOMP 0.108 0.090 0.711 0.050 0.035
sPIIINP 0.138 0.185 0.685 0.224 0.046
sHA 0.077 0.138 0.653 0.195 0.093
sC12C 0.062 0.112 0.088 0.672 0.037
pResistin 0.074 0.266 0.033 L0.570 0.058
pAdiponectin 0.358 0.074 0.001 0.526 0.002
sPIIANP 0.022 0.178 0.049 0.021 0.759
sCS846 0.021 0.016 0.116 0.015 0.678
‘Eigenvalues’ 3.406 1.927 1.681 1.381 1.143
% Of variance 21.7 12.8 8.8 7.5 6.7
Cronbach’s alphas 0.842 0.619 0.327 0.252 0.173
W.E. van Spil et al. / Osteoarthritis and Cartilage 20 (2012) 745e754748levels that were assessed in each of the plates per day and averaged
for all days. Between-day CV% was calculated from the mean
biomarker levels in the standard samples that were assessed at
each of the days.
Principal component analysis was performed to enable identi-
ﬁcation of clusters of interrelated biomarkers (components) within
the spectrum of biomarkers. Biomarker levels were logarithmically
transformed to obtain normal distributions. Direct Oblimin oblique
rotation of the factor loadings, allowing for correlation among
factors, was performed since the biomarkers were expected to
originate from distinct but interrelated processes in the OA joint(s).
Associations between biomarker levels and demographic vari-
ables were investigated by multiple linear regression analysis. In
each model one of the biomarkers was used as dependent variable,
with demographics as independent variables. Biomarker levels and
BMI were logarithmically transformed to obtain normally distrib-
uted variables and, thereby, residuals.
Modiﬁcation of the association of age and BMI with biomarker
levels by gender and/or menopause (e.g., different association of
age with biomarker levels between genders) was investigated
through interaction terms. When interaction terms appeared to be
statistically signiﬁcant, now deﬁned as P < 0.200, analyses were
repeated separately in gender or menopause subgroups for the
biomarker concerned (i.e., stratiﬁed analyses).
To facilitate direct comparison between regression coefﬁcients
of variables and models, coefﬁcients are expressed as standardized
betas. Standardized betas represent the number of SDs that the
outcome will change as a result of one SD change in the predictor
and are therefore independent of the units of measurement of the
variables and can vary between 1 and 1.
All statistical analyses were performed using SPSS 15.0. Statis-
tical signiﬁcance was deﬁned as P < 0.05, unless stated otherwise.
Results
The numbers of participants for whom biomarker datawere and
were not obtained are tabulated in Table II. Missing data were due
to absent sample tubes (lost at the stage of sample collection,
storage, and/or recollection) or too small sample volumes to
perform all assessments. Data represented here are inclusive of the
arbitrary biomarker levels for samples outside standard curves (80%
minimum,120% maximum). Results were similar between analyses
with and without these arbitrary biomarker levels and when
outliers were alternatively set at 100% of minimum and maximum
biomarker levels (i.e., sensitivity analysis) (data not shown).
Intra-plate, inter-plate, and between-day CV%’s for all
biomarkers are tabulated in Table II. Especially the assessment of
sC1,2C and sCS846 showed low precision (i.e., high CV%), probably
related to the aforementioned technical issues. sHA, sPIIANP and
pAdiponectin also showed considerable variability, but otherwise
unremarkable quality controls (e.g., internal control samples, blank
samples, gradients, data not shown).
Principal component analysis was performed to investigate
mutual associations between biomarkers, adipokines, hsCRP, and
ESR. When all participants were included in the analysis, all vari-
ables that were introduced in the model showed communalities
0.371, indicating that they all shared considerable variance (i.e.,
37.1%) with any other variable(s) and including them in the
analysis was appropriate. Five components had ‘eigenvalues’ 1,
with the ﬁfth component having an ‘eigenvalue’ of only 1.143
(Table IIIA and online supplementary data). Accordingly, the point
of inﬂexion of the scree plot indicated that four components would
represent the variation in the dataset most optimally (i.e., most
optimal balance between complexity of the model and reﬂection of
the variation in the dataset). Therefore, also a (forced) four-component model was investigated (Table SII). This time, sCS846
and sPIIANP that were already in the ﬁfth component of the ﬁrst
model expectedly had very low communalities of 0.070 and 0.148,
respectively (i.e., their variation could not be explained adequately
by this model). After exclusion of sCS846 and sPIIANP, the
remaining components of the model were almost identical to the
original model. Since our goal was to determine the underlying
domains in our complete dataset the ﬁrst (ﬁve-component) model
was considered our primary model. Nevertheless, the secondary
model showed that sCS846 and sPIIANP were not so closely asso-
ciated with the remaining variables. When variables in the primary
analysis were categorized per component on the basis of maximum
loading factors, components were as follows: Component 1 e
uCTX-I, uNTX-I, sPINP, sOC, and uCTX-II, designated ‘bone-CTX-II’
cluster, component 2 e ESR, pLeptin, and hsCRP, designated
‘inﬂammation’ cluster, component 3 e sCOMP, sPIIINP, and sHA,
designated ‘synovium’ cluster, component 4e sC12C, pResistin, and
pAdiponectin, designated ‘C1,2C-adipokines’ cluster, and compo-
nent 5 e sPIIANP, sCS846, designated ‘cartilage synthesis’ cluster.
Correlations among components were only very weak (maximum
Pearson’s correlation coefﬁcient ¼ 0.154, data not shown).
To determine whether these mutual associations between
variables were dependent of radiographic OA status, the principal
component analysis was repeated in participants with and without
radiographic knee and/or hip OA separately (K&L grade 1 for one
or more joints and K&L ¼ 0 for all joints, respectively). The
component structure in participants without radiographic OA was
almost identical to that in the whole cohort (Tables SIII and SIV).
However, in participants with radiographic OA some small differ-
ences were observed (Table IIIB and online supplementary data).
This time, six components had ‘eigenvalues’ 1. uCTX-II still loaded
to a comparable extent (loading factor 0.494) on the ﬁrst compo-
nent of bone markers, but this time loaded slightly more (loading
factor 0.566) on the ﬁfth component together with sPIIANP.
Furthermore, sHA loaded on the sixth component together with
sCS846. These ﬁfth and six components had ‘eigenvalues’ of only
1.094 and 1.027, respectively, and the point of inﬂexion of the scree
plot suggested four components as the most optimal model. When
Table IIIB
1 2 3 4 5 6
uCTX-I 0.908 0.077 0.008 0.057 0.139 0.012
uNTX-I 0.854 0.149 0.024 0.074 0.191 0.030
sPINP 0.847 0.047 0.309 0.055 0.037 0.042
sOC 0.793 0.084 0.237 0.218 0.051 0.117
pLeptin 0.073 0.779 0.075 0.078 0.063 0.090
ESR 0.067 0.761 0.065 0.148 0.031 0.022
hsCRP 0.166 0.719 0.013 0.456 0.096 0.104
sCOMP 0.088 0.041 0.784 0.154 0.092 0.020
sPIIINP 0.144 0.153 0.698 0.139 0.143 0.073
sC12C 0.059 0.029 0.082 0.647 0.061 0.048
pAdiponectin 0.316 0.008 0.053 0.605 0.055 0.217
pResistin 0.147 0.222 0.135 L0.540 0.156 0.205
sPIIANP 0.015 0.180 0.002 0.011 0.829 0.131
uCTX-II 0.494 0.345 0.213 0.016 L0.566 0.193
sCS846 0.008 0.023 0.019 0.019 0.124 0.822
sHA 0.008 0.140 0.486 0.056 0.248 0.552
‘Eigenvalues’ 3.427 2.080 1.444 1.230 1.094 1.027
% Of variance 21.4 13.0 9.0 7.7 6.8 6.4
Cronbach’s
alphas
0.832 0.654 0.364 0.218 0.278 0.237
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sixth component expectedly showed a low communality (0.132) and
was excluded. uCTX-II, as before, clustered with the bone markers.
sHA clustered with pLeptin, hsCRP, and ESR (Table SV).
Associations between demographics and biomarker levels are
tabulated in Tables IV and V. Especially pLeptin, ESR, uCTX-I, and
uNTX-I showed higher levels in women as compared to men
(Table IV, left). Age was strongly associated with sHA and uCTX-II
levels. BMI appeared to be strongly associated with pLeptin
levels. Furthermore, postmenopausal women showed higher levels
of all bone markers, uCTX-II, and sCOMP than premenopausal
women (Table V, left). sCS846, by contrast, did not show any
association with demographics. Statistically signiﬁcant modiﬁca-
tion of the association of age and BMI with biomarker levels by
gender (Table IV, middle) and/or menopausal status (Table V,
middle) was mostly found for the biomarkers of bone metabolism.
Especially associations of bone marker and uCTX-II levels with age
differed between genders and between premenopausal and post-
menopausal women: men and postmenopausal women showed no
(or borderline signiﬁcant) associations between age and biomarker
levels, while premenopausal women showed positive associations
(Tables IV and V, right).
Discussion
The current biomarker dataset in subjects with early symp-
tomatic knee and/or hip OA is the largest in its kind and is especially
valuable for its focus on early rather than late-stage disease.
The majority of biomarkers showed relevant associations with
demographics, which were expectedly different between genders
and/or menopausal status for some. Increased bone marker levels
in postmenopausal women as compared to premenopausal women
and men have been reported before19e23. In our study, bone
markers were not associated with age in postmenopausal women
but positively associated with age in our premenopausal women
aged >45 years. This is in accordance with data from other authors
demonstrating increasing bone marker levels during the age
interval 45e60 years and stable plateau levels thereafter20,22,24.
Men, by contrast, did not show associations between bone markers
and age. Indeed, stable bone marker levels have been reported for
men aged 45e65 years23e25. Also the negative associations
between all biomarkers of bone metabolism and BMI are in
accordance with literature on healthy subjects20,26e29.In our study, sCS846 did not show associations with demo-
graphics, as was also observed by Conrozier et al. in 56 hip OA
patients30. Possibly, this absence of associations with demographics
in our study may also be attributable to the observed low precision
(i.e. high CV%) and concentration gradients within assay plates.
Our data on associations between demographics and uCTX-II are in
accordance with a study by Mouritzen et al. in healthy subjects
showing increasing uCTX-II levels in women aged 50e55 years
followed by a stable plateau phase, higher uCTX-II levels in post-
menopausal women as compared to premenopausal women
matched for age and BMI, and positive associations between uCTX-
II and BMI24. Also our data on sCOMPwere comparable to data from
Jordan et al. on sCOMP levels in 769 randomly selected subjects
from the Johnston County Osteoarthritis Project31. They demon-
strated sCOMP levels to be positively associated with age and BMI
and lower sCOMP levels in women than in men.
Principal component analysis enabled identiﬁcation of clusters
of interrelated biomarkerswithin the biomarker spectrum. Theﬁrst,
‘bone-CTX-II’, cluster not only contained bone markers but also
uCTX-II, which is supposed to be a marker of collagen type II
degradation, and with that of cartilage matrix degradation. This
observation does not stand on its own32, since also other authors
have observed associations between uCTX-II and bonemarkers33e35
and Garnero et al. showed CTX-I, PINP and CTX-II loading onto one
cluster in the ECHODIAH cohort of hip OA patients36. Accordingly,
uCTX-II has been suggested tobeprimarily derived fromosteoclastic
resorption of calciﬁed cartilage37. Interesting in this respect may be
the localization of CTX-II epitope release at the cartilageebone
interface38. Using uCTX-II as a marker of (solely) cartilage degra-
dation in clinical studies may be misleading, especially in trials of
agents that inﬂuence bonemetabolism. uCTX-II does not only reﬂect
bone metabolism as is evidenced by the fact that uCTX-II also
loaded to a considerable extent onto other components. Apparently,
uCTX-II levels are associated with inﬂammation, synovial metabo-
lism, and cartilage metabolism in addition to bone metabolism.
uCTX-II was more strongly, inversely, associated with PIIANP in
participants with radiographic signs of OA, which may reﬂect the
uncoupling between cartilage synthesis and degradation that is
presumed to be present in OA patients39.
The second, ‘inﬂammation’, cluster contained pLeptin, hsCRP,
and ESR, all associated with (systemic) inﬂammation and cardio-
vascular disease/metabolic syndrome40. This cluster did not show
so many associations with biomarkers of joint metabolism, except
for uCTX-II (mentioned above) and sHA in the four-component
model in subjects with radiographic OA. The latter may reﬂect the
synovitis that may be present to a higher extent in these subjects.
The third, ‘synovium’, cluster contained biomarkers that have
been related to the low-grade synovitis that is present in OA:
sPIIINP41, sHA42, and sCOMP. Again, Garnero et al. showed exactly
the same component in the ECHODIAH cohort36. sCOMP has been
demonstrated to be present in synovial tissue, to be produced by
synoviocytes43, and associated with clinically44,45 and ultrasono-
graphically diagnosed42 synovitis and/or effusion in OA. sCOMP
levels should not only be interpreted in the context of cartilage
degradation46, but should also be interpreted in the context of
synovitis. Bone synthesis markers showed some positive associa-
tions with this cluster, possibly reﬂecting a link between osteo-
phytosis and synovitis42.
The fourth, ‘C1,2C-adipokines’, cluster contained sC1,2C, pRe-
sistin, and pAdiponectin. Literature on adipokines and C1,2C is
scarce. One small study showed increased C1,2C levels upon adipo-
nectin stimulation of ex vivo OA cartilage explants7, which is exactly
opposite our ﬁndings. This and the third, ‘inﬂammation’, cluster did
not show somanyassociationswith biomarkers of jointmetabolism,
arguing against major involvement of adipokines in OA.
Table IV
Associations between demographic variables and biomarkers for all participants and for genders separately when interaction terms with gender (men as reference) were statistically signiﬁcant. Associations were investigated
through multiple linear regression analyses with in each model one of the biomarkers as dependent variable and in all models demographic variables as independent variables. Statistically signiﬁcant results are bold (P < 0.200
for interaction terms)
Gender Age BMI Interaction terms Male Female
Gender*age Gender*BMI Age BMI Age BMI
Stand beta P Stand beta P Stand beta P P P Stand beta P Stand beta P Stand beta P Stand beta P
Cartilage
uCTX-II 0.191 <0.001 0.242 <0.001 0.112 <0.001 0.029 0.492 0.159 0.023 0.267 <0.001
sCOMP 0.157 <0.001 0.184 <0.001 0.173 <0.001 0.353 0.622
sPIIANP 0.059 0.070 0.075 0.020 0.099 0.002 0.918 0.316
sCS846 0.000 0.989 0.031 0.339 0.061 0.063 0.167 0.533 0.132 0.064 0.006 0.871
Cartilage/bone
sC1,2C 0.125 <0.001 0.030 0.349 0.093 0.004 0.699 0.847
Bone
uCTX-I 0.278 <0.001 0.160 <0.001 0.137 <0.001 0.001 0.422 0.021 0.767 0.211 <0.001
uNTX-I 0.291 <0.001 0.183 <0.001 0.111 <0.001 0.025 0.472 0.073 0.304 0.221 <0.001
sPINP 0.173 <0.001 0.124 <0.001 0.100 0.002 0.006 0.264 0.047 0.513 0.165 <0.001
sOC 0.130 <0.001 0.170 <0.001 0.176 <0.001 0.001 0.345 0.019 0.785 0.212 <0.001
Synovium
sHA 0.084 0.005 0.367 <0.001 0.117 <0.001 0.014 0.442 0.299 <0.001 0.388 <0.001
sPIIINP 0.027 0.390 0.034 0.284 0.229 <0.001 0.533 0.062 0.318 <0.001 0.208 <0.001
Adipokines
pAdiponectin 0.320 <0.001 0.149 <0.001 0.243 <0.001 0.211 0.113 0.156 0.026 0.276 <0.001
pLeptin 0.548 <0.001 0.010 0.585 0.596 <0.001 0.905 0.923
pResistin 0.041 0.204 0.025 0.427 0.160 <0.001 0.216 0.426
Inﬂammation
hsCRP 0.074 0.013 0.038 0.200 0.393 <0.001 0.945 0.711
ESR 0.318 <0.001 0.106 0.001 0.173 <0.001 0.433 0.023 0.017 0.811 0.220 <0.001
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Table V
Associations between demographic variables and biomarkers for women and for premenopausal and postmenopausal women separately when interaction terms with menopausal status (premenopausal women as reference)
were statistically signiﬁcant. Associations were investigated through multiple linear regression analyses with in each model one of the biomarkers as dependent variable and in all models demographic variables as independent
variables. Statistically signiﬁcant results are bold (P < 0.200 for interaction terms)
Menopausal status Age BMI Interaction terms Premenopausal women Postmenopausal women
Menop*age Menop*BMI Age BMI Age BMI
Stand beta P Stand beta P Stand beta P P P Stand beta P Stand beta P Stand beta P Stand beta P
Cartilage
uCTX-II 0.137 0.008 0.188 <0.001 0.084 0.035 0.003 0.678 0.368 <0.001 0.096 0.041
sCOMP 0.122 0.022 0.062 0.241 0.141 0.001 0.010 0.890 0.245 0.004 0.000 0.998
sPIIANP 0.031 0.559 0.051 0.339 0.099 0.016 0.701 0.828
sCS846 0.033 0.535 0.015 0.775 0.065 0.119 0.866 0.922
Cartilage-bone
sC1,2C 0.002 0.970 0.018 0.740 0.120 0.004 0.069 0.400 0.160 0.067 0.022 0.644
Bone
uCTX-I 0.239 <0.001 0.051 0.323 0.179 <0.001 <0.001 0.023 0.371 <0.001 0.015 0.853 0.042 0.366 0.238 <0.001
uNTX-I 0.207 <0.001 0.079 0.127 0.147 <0.001 <0.001 0.057 0.332 <0.001 0.008 0.927 0.008 0.927 0.197 <0.001
sPINP 0.240 <0.001 0.020 0.696 0.164 <0.001 <0.001 0.006 0.276 0.001 0.037 0.662 0.092 0.045 0.231 <0.001
sOC 0.256 <0.001 0.022 0.662 0.239 <0.001 <0.001 0.048 0.323 <0.001 0.093 0.264 0.064 0.156 0.299 <0.001
Synovium
sHA 0.075 0.130 0.333 <0.001 0.108 0.005 0.668 0.384
sPIIINP 0.065 0.219 0.017 0.754 0.180 <0.001 0.596 0.664
Adipokines
pAdiponectin 0.050 0.326 0.065 0.203 0.296 <0.001 0.114 0.512 0.232 0.006 0.010 0.829
pLeptin 0.014 0.700 0.006 0.871 0.735 <0.001 0.874 0.349
pResistin 0.092 0.080 0.009 0.868 0.177 <0.001 0.412 0.155 0.033 0.704 0.227 <0.001
Inﬂammation
hsCRP 0.055 0.264 0.085 0.083 0.426 <0.001 0.486 0.415
BSE 0.028 0.597 0.089 0.092 0.197 <0.001 0.781 0.528
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W.E. van Spil et al. / Osteoarthritis and Cartilage 20 (2012) 745e754752The ﬁfth, ‘cartilage synthesis’, cluster contained sPIIANP and
sCS846. Both are indicative of synthesis of cartilage matrix, sPIIANP
representing collagen synthesis38,39 and sCS846 representing
glycosaminoglycan synthesis47. Accordingly, Otterness et al. showed
CS846 and C-propeptide of type II collagen (associated with type II
collagen synthesis) loading onto one component48. We do not have
a clear explanation for the association between sHA and sCS846 that
was speciﬁcally observed in the sixth cluster in subjects with
radiographic OA. Possibly, in these subjects synovitis has some
associationwith cartilage synthesis, althoughwewould then rather
expect sHA and sCS846 loading inversely onto this cluster.
Interpretation of the, mostly rather low, Cronbach’s alphas of
the identiﬁed clusters is not so straightforward. Although they
might indicate that biomarkers in the clusters concerned do not
represent one underlying domain, which may be true, they prob-
ably also represent the variable metabolism and kinetics between
biomarkers.
Concluding, the observed associations between biomarkers and
demographics as well as the identiﬁed biomarker clusters extended
on literature on individual biomarkers and our own expertise. This
was interpreted as evidence for validity of our biomarker dataset.
Also, some interesting associations were observed that warrant
more cautious interpretation of some biomarkers than is normally
done in current biomarker literature.
Obvious strengths of the current study are its size, the multiple
biomarkers and adipokines that were assessed simultaneously, and
the small numbers of missing biomarker data. Of course, this study
has limitations also. First of all, biomarkers were only assessed in
baseline samples. Serial biomarker assessments in this longitudinal
cohort would also be very valuable and may be performed in the
future. Secondly, a healthy control group would have been inter-
esting to compare (associations between) biomarkers between
healthy and OA subjects, but was not included in our study. Thirdly,
a major limitation of biomarkers in general is the uncertainty about
the biological process(es) they reﬂect. Furthermore, associations
between systemic biomarker levels and jointmetabolism, if any, are
potentially obscured by factors such as variable biomarker release
from joints due to physical activity49 and extra-articular metabo-
lism50. Finally, it should be emphasized that further studies would
be needed to conﬁrm the component structure that was found in
our biomarker dataset. Especially interesting in this perspective
will be the biomarker assessment that is planned in the Osteoar-
thritis Initiative (OAI).
Altogether we believe that we have performed valid assessment
of a wide spectrum of biomarkers in CHECK, a 10-year prospective
cohort of 1,002 subjects with (very) early symptomatic OA. These
data will prove invaluable for future analyses of cross-sectional and
predictive relations between biomarkers and structural and clinical
joint parameters in early knee and hip OA.
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